Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

50
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
50
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

52
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
52
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.

Nature cardiovascular research·2026
Same author

Frailty and Congestion in Patients with Heart Failure: Clinical Interaction and Prognostic Implications.

Journal of clinical medicine·2026
Same author

Repurposing polyamines to prevent life-threatening arrhythmias in Short QT Syndrome type 3.

Nature communications·2026
Same author

Telomere length dynamics do not predict subclinical atherosclerosis progression over a six-year period.

GeroScience·2026
Same author

MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis.

Circulation·2026
Same author

Impact of Lipoprotein(a) on Residual Cardiovascular Risk After an Acute Coronary Syndrome.

Journal of clinical medicine·2026

Video Experimental Relacionado

Updated: Sep 9, 2025

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.3K

Genotipos arritmicos en cardiomiopatía dilatada y riesgo de insuficiencia cardíaca avanzada

Nerea Mora-Ayestarán1,2,3, Juan Pablo Ochoa4, Cristina Gómez-González2,3,5,6,7

  • 1Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, Manuel de Falla 1, Majadahonda, 28222 Madrid, Spain.

European heart journal
|August 29, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Los pacientes con genotipos de cardiomiopatía dilatada (DCM) de alto riesgo enfrentan un aumento de los eventos de insuficiencia cardíaca avanzada (AHF). Este hallazgo sugiere terapias personalizadas para pacientes con DCM más allá de la prevención de la muerte súbita cardíaca.

Palabras clave:
Miocardiopatía dilatadaLos genesInsuficiencia cardíacaEl pronósticoMuerte súbita por ataque cardíaco

Más Videos Relacionados

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.7K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.3K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.7K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K

Área de la Ciencia:

  • Cardiología
  • La genética
  • Investigación de la insuficiencia cardíaca

Sus antecedentes:

  • La cardiomiopatía dilatada (DCM) tiene subtipos genéticos con diferentes riesgos.
  • No se comprende bien la asociación entre los genotipos arritmicos de alto riesgo y las complicaciones de insuficiencia cardíaca avanzada (AHF) en DCM.

Objetivo del estudio:

  • Investigar si los pacientes con DCM con genotipos arritmicos de alto riesgo experimentan más eventos de AHF.
  • Para analizar la relación entre el genotipo DCM y las complicaciones de AHF.

Principales métodos:

  • Se analizó una cohorte de 1203 pacientes con DCM genotipados.
  • Los pacientes fueron categorizados en genotipos de alto riesgo, variantes TTN, otras variantes genéticas y grupos con genotipo negativo.
  • El criterio de valoración primario: compuesto de eventos de FHA (implantación del dispositivo, trasplante, mortalidad); el criterio de valoración secundario: arritmias ventriculares malignas (AVM).

Principales resultados:

  • El 15,4% de los pacientes presentaba genotipos arritmicos de alto riesgo.
  • Los pacientes con genotipo de alto riesgo mostraron una incidencia significativamente mayor de eventos de FHA (24,3%) en comparación con otros grupos (10,1-18,7%).
  • El genotipo de arritmia de alto riesgo fue un predictor independiente de AHF y MVA.

Conclusiones:

  • Los pacientes con DCM con genotipos arritmicos de alto riesgo experimentan una mayor carga de eventos de AHF.
  • Estos hallazgos apoyan la necesidad de estrategias terapéuticas distintas para este subgrupo de pacientes, que vayan más allá del tratamiento de la arritmia.